December 27th, 2016
•Biofilm infections show high tolerance towards chemotherapy. No single assay captures the complexity of biofilms. Instead, complementary assays are needed. We present a screening platform (developed for S. aureus) that combines assays for viability, biomass, and biofilm matrix. It allows anti-biofilm drug discovery, including the assessment of long-term chemotherapeutic effects.
Related Videos
Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays Video (Video) | JoVE
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries Video (Video) | JoVE
Qualitative and Quantitative Assays for Detection and Characterization of Protein Antimicrobials Video (Video) | JoVE
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response Video (Video) | JoVE
Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli Video (Video) | JoVE
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers Video (Video) | JoVE
A Novel Feeder-free System for Mass Production of Murine Natural Killer Cells In Vitro Video (Video) | JoVE
Combining Analysis of DNA in a Crude Virion Extraction with the Analysis of RNA from Infected Leaves to Discover New Virus Genomes Video (Video) | JoVE
A High-throughput Platform for the Screening of Salmonella spp./Shigella spp. Video (Video) | JoVE
Automated Behavioral Analysis of Large C. elegans Populations Using a Wide Field-of-view Tracking Platform Video (Video) | JoVE
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved